What AI says about Soligenix

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with unmet medical needs. Its Specialized BioTherapeutics pipeline includes HyBryte for Cutaneous T-Cell Lymphoma, SGX302 for mild-to-moderate plaque psoriasis, SGX942 for oral mucositis, and SGX945 for aphthous ulcers in Behçet’s Disease, spanning preclinical to Phase 3 and NDA review. The company also runs Public Health Solutions programs funded by the U.S. government, including RiVax to prevent ricin poisoning and ThermoVax thermostable vaccines for global use.